{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"056-973-188-183-649","frontPageModel":{"patentViewModel":{"ref":{"entityRefId":"056-973-188-183-649","entityRefType":"PATENT"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":8901,"type":"PATENT","title":"University of Michigan Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":14369,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8216,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners= \"Univ Michigan\", \" Michigan Univ\", \" Univ Michigan NOT state NOT tech NOT Eastern\", \"Univ Michigan NOT technological\", \" Univ Michigan NOT Western\"
Select more for logical variants
Add to collection
Total patent : 14104
Search Applicants and Owners= \"Univ Michigan\", \" Michigan Univ\", \" Univ Michigan NOT state NOT tech NOT Eastern\", \"Univ Michigan NOT technological\", \" Univ Michigan NOT Western\"
Select more for logical variants
Add to collection
Total patent : 14104
a) processing an initial sample from a subject under conditions such that an isolated T-cell sample is generated,\n
wherein said initial sample is selected from: a peripheral blood sample, a spleen sample, and a lymph node sample, and\n
wherein said isolated T-cell sample comprises purified cells, wherein substantially all of said purified cells present in said T-cell sample are unprimed CD44− CD8+ T-cells as a result of said processing; and\n
b) contacting said isolated T-cell sample, which contains said unprimed CD44− CD8− T-cells, with: i) an antigen, ii) antigen presenting cells, and iii) an mTOR pathway inhibiting agent, under conditions such that a memory T-cell sample is generated that comprises memory T-cells specific to said antigen, wherein substantially all of said memory T-cells present in said memory T-cell sample are CD44− CD62L+ CD8+;\n
wherein said mTOR pathway inhibiting agent is selected from the group consisting of: rapamycin, temsirolimus, everolimus torin, and deforolimus."],"number":1,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein said isolated T-cell sample is further contacted with at least one cytokine."],"number":2,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 2, wherein said at least one cytokine comprises IL-2."],"number":3,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 2, wherein said at least one cytokine comprises IL-21."],"number":4,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 2, wherein said at least one cytokine is IL-2 and IL-21."],"number":5,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein said CD44− CD62L+ CD8+ memory T cells express elevated levels, relative to cells in said initial sample, of at least one gene selected from the group consisting of: Ezh2, Hells, Bmi1, Survivin, p18Ink4c, and p21."],"number":6,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein said CD44− CD62L+ CD8+ memory T cells express elevated levels, relative to cells in said initial sample, of each of the following genes: Ezh2, Hells, Bmi1, Survivin, p18Ink4c, and p21."],"number":7,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein said contacting further comprises contacting said isolated T-cell sample with IL-15."],"number":8,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein said antigen is a tumor-associated antigen."],"number":9,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein said mTOR pathway-inhibiting agent comprises rapamycin."],"number":10,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein said unprimed CD44− CD8+ T-cells are human T-cells."],"number":11,"annotation":false,"claim":true,"title":false}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}